About 8 results found for searched term "Cytarabine" (0.155 seconds)
Cat.No. | Name | Target |
---|---|---|
M2292 | Cytarabine | DNA/RNA Synthesis |
Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C | ||
Cytarabine (Cytosine arabinoside, AraC) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM. | ||
M13643 | Cytarabine hydrochloride | DNA/RNA Synthesis |
Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride | ||
Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV. | ||
M57984 | Aspacytarabine | Others |
Aspacytarabine | ||
M21481 | MBC-11 | Others |
MBC-11 is a first-in-class, bone-targeted bisphosphonate conjugate covalently bound to the antimetabolite cytarabine (araC). MBC-11 has the potential to be used in neoplastic bone disease (TIBD). | ||
M21483 | MBC-11 triethylamine | Others |
MBC-11 triethylamine is the first (first-in-class), bone-targeted ethyl bisphosphonate covalently bound conjugate to the antimetabolite cytarabine (araC). MBC-11 triethylamine has the potential to be used in neoplastic bone disease (TIBD).*The compound is unstable in solutions, freshly prepared is recommended | ||
M21484 | MBC-11 trisodium | Others |
MBC-11 trisodium is a first-in-class coupling of bone-targeted ethyl bisphosphonate covalently bound to the antimetabolite cytarabine (Ara-C). MBC-11 trisodium has the potential to be used in neoplastic bone disease (TIBD). | ||
M28560 | Sapacitabine | Nucleoside Antimetabolite/Analog |
CS682; CYC682 | ||
Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine. | ||
M41306 | Ara-SH | Apoptosis |
Ara-SH is a Cytarabine mercaptopropionic acid-substituted derivative. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.